DK143088D0 - Praeparat til behandling eller forhindring af virale infektioner - Google Patents

Praeparat til behandling eller forhindring af virale infektioner

Info

Publication number
DK143088D0
DK143088D0 DK143088A DK143088A DK143088D0 DK 143088 D0 DK143088 D0 DK 143088D0 DK 143088 A DK143088 A DK 143088A DK 143088 A DK143088 A DK 143088A DK 143088 D0 DK143088 D0 DK 143088D0
Authority
DK
Denmark
Prior art keywords
treating
preparation
viral infections
preventing viral
steroids
Prior art date
Application number
DK143088A
Other languages
English (en)
Other versions
DK143088A (da
Inventor
Anthony Atkinson
Graham Lloyd
Peter Morgan Sutton
Original Assignee
Health Lab Service Board
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Lab Service Board filed Critical Health Lab Service Board
Publication of DK143088D0 publication Critical patent/DK143088D0/da
Publication of DK143088A publication Critical patent/DK143088A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK143088A 1987-03-17 1988-03-16 Praeparat til behandling eller forhindring af virale infektioner DK143088A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878706313A GB8706313D0 (en) 1987-03-17 1987-03-17 Treatment & prevention of viral infections

Publications (2)

Publication Number Publication Date
DK143088D0 true DK143088D0 (da) 1988-03-16
DK143088A DK143088A (da) 1988-09-18

Family

ID=10614085

Family Applications (1)

Application Number Title Priority Date Filing Date
DK143088A DK143088A (da) 1987-03-17 1988-03-16 Praeparat til behandling eller forhindring af virale infektioner

Country Status (10)

Country Link
US (1) US4957910A (da)
EP (1) EP0285285B1 (da)
JP (1) JPS63301823A (da)
AT (1) ATE106729T1 (da)
AU (1) AU619174B2 (da)
CA (1) CA1317224C (da)
DE (1) DE3889964T2 (da)
DK (1) DK143088A (da)
GB (1) GB8706313D0 (da)
ZA (1) ZA881856B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO178843C (no) * 1988-07-11 1996-06-19 Sspl Sa Safe Sex Prod Licens Fremgangsmåte for fremstilling av et farmasöytisk preparat for å forhindre seksuelt overförbare sykdommer
WO1990003172A2 (en) * 1988-09-20 1990-04-05 Fisons Plc Bile acids for treatment of viral infections
DK603988D0 (da) * 1988-10-28 1988-10-28 Klaus Bendtzen Farmaceutisk praeparat
US5079240A (en) * 1990-03-15 1992-01-07 The Regents Of The University Of California Synthetic conjugated bile acid and method of use thereof
US5206008A (en) * 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
IT1255450B (it) * 1992-06-30 1995-10-31 Montefarmaco Spa Uso di acidi biliari come agenti antivirali
IL108748A0 (en) * 1993-02-23 1994-08-26 Univ Princeton Solution and solid-phase formation of glycosidic linkages
US5639866A (en) * 1993-02-23 1997-06-17 Princeton University Single-step formation of multiple glycosidic linkages
DE4316347C1 (de) * 1993-02-26 1994-08-18 Ina Dr Levi Verfahren zur Herstellung einer pharmazeutischen Zubereitung und Verwendung derselben zur Behandlung bestimmter Erkrankungen
CA2167537A1 (en) * 1993-07-19 1995-02-02 Tsuneo Ozeki Hepatitis c virus proliferation inhibitor
CN1132586C (zh) * 1993-09-09 2003-12-31 罗拉斯医疗公司 来自胆汁的免疫调节组合物、其制备方法及其用途
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US5658560A (en) * 1994-01-18 1997-08-19 Serikov; Vladimir B. Method of treating endotoxemia by administering tyloxapol
US5646316A (en) * 1994-04-08 1997-07-08 Osteoarthritis Sciences, Inc. Bile acid inhibitors of metalloproteinase enzymes
NZ302638A (en) 1995-03-16 2001-04-27 Imutec Pharma Inc Immunomodulating composition from bile for the treatment of immune system disorders
IT1282943B1 (it) * 1995-12-27 1998-04-02 Sanofi Winthrop S P A Composizione farmaceutica iniettabile__a base di acido ursodesossicoli co o tauroursodesossicolico
DE19631122A1 (de) * 1996-08-01 1998-02-05 Falk Pharma Gmbh Verwendung von Ursodeoxycholsäure bei HIV-Infektion
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
EP1333847A1 (en) * 2000-11-08 2003-08-13 Lorus Therapeutics Inc. Combination preparation of a biological response modidier and an anticancer agent and uses thereof
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
WO2002102363A1 (en) * 2001-06-20 2002-12-27 Lorus Therapeutics Inc. Biological response modifier composition and uses thereof
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CN103223160B (zh) * 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
CN103570790B (zh) * 2012-08-07 2016-06-01 中国科学院上海药物研究所 原人参二醇衍生物及其制备方法、包含该衍生物的组合物及其用途
CN107531741A (zh) 2015-03-10 2018-01-02 美莱斯股份有限公司 氟化和烷基化胆酸
CN114173578A (zh) 2019-05-14 2022-03-11 迪美公司 用于治疗癌症的组合物和方法
US10905698B1 (en) * 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2021231931A1 (en) * 2020-05-14 2021-11-18 Tyme, Inc. Methods of treating sars-cov-2 infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE44263B1 (en) * 1975-12-03 1981-09-23 Leo Pharm Prod Ltd New fusidic acid derivatives
GB8417895D0 (en) * 1984-07-13 1984-08-15 Marples B A Pharmaceutical anti-fungal composition

Also Published As

Publication number Publication date
EP0285285A2 (en) 1988-10-05
DK143088A (da) 1988-09-18
GB8706313D0 (en) 1987-04-23
AU619174B2 (en) 1992-01-23
ATE106729T1 (de) 1994-06-15
JPS63301823A (ja) 1988-12-08
EP0285285A3 (en) 1990-12-05
ZA881856B (en) 1989-04-26
CA1317224C (en) 1993-05-04
EP0285285B1 (en) 1994-06-08
AU1321688A (en) 1988-09-15
DE3889964T2 (de) 1994-09-15
US4957910A (en) 1990-09-18
DE3889964D1 (de) 1994-07-14

Similar Documents

Publication Publication Date Title
DK143088A (da) Praeparat til behandling eller forhindring af virale infektioner
ES2194902T3 (es) L-nucleosidos para el tratamiento del virus de la hepatitis b y el virus de epstein barr.
DK0428642T3 (da) Anvendelse af C-22 til C-26 alifatiske alkoholer til behandling af betændelses- og virussygdomme
FI20001231A7 (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
PT88930A (pt) Processo para a preparacao de novos analogos de nucleosidos e de composicoes farmaceuticas que os contem
JPS57140724A (en) Heat-treatment of aqueous solution containing cold insoluble globulin
NO883564D0 (no) Topisk aktive preparater av dobbeltraadet rna.
DE229016T1 (de) Interleukin-2-zusammensetzungen.
DK538888A (da) Anvendelse af castanosperminestere til fremstilling af et farmaceutisk praeparat
ATE64669T1 (de) Verfahren zur verfestigung von nuklearen abfaellen in borsilikatglas.
NO970847L (no) 2-£amino-6-(cyklopropylamino)-9H-purin-9-yl|-2-cyklopenten-1-metanol-succinat som anti-virusmiddel
ATE82294T1 (de) Therapeutische nukleoside.
EE9400068A (et) Ravimsegud viirushepatiidi B (HBV) infektsiooni ja selle poolt p6hjustatud haiguste raviks ja nende valmistamise protsess
IT1050327B (it) Soluzioni concentrate stabili di coloranti contenenti gruppi solfonici processo per la loro preparazione e loro impiego
JPS51118820A (en) A process for preparing heat stable macroglobulin
DK0504191T3 (da) Præparat til behandling af HIV-infektioner
GR3014952T3 (en) Use of an immunoglobulin-containing composition in the prophylaxis and therapy of AIDS of human.
ATE88752T1 (de) Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole.
SE7904840L (sv) Antiviralt verksamma t-rna-preparat
SE8008456L (sv) Komposition och framstellning derav
ATE94766T1 (de) Verfahren zur herstellung einer galenischen zubereitung mit optimaler bioverfuegbarkeit des wirkstoffs 2-hydroxy-5-methyllaurophenonoxime (hmlo).
SU955690A1 (ru) Способ концентрирования вируса ящура
FR1258601A (fr) Procédé de préparation de bleu de prusse et pigments analogues à partir de l'acide cyanhydrique, du sulfate ferreux et de bases
ES8602354A1 (es) Procedimiento para la limpieza desinfectante de superficies duras

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment